You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Wearable Ultralow Power Personal Exposure Monitor for Atmospheric Pollutants

    SBC: KWJ Engineering Inc.            Topic: NIEHS

    DESCRIPTION provided by applicant The goal of this STTR Phase I collaboration between KWJ Engineering KWJ and North Carolina State University NCSU will be development of a unique autonomously powered wearable environmental gas sensor for personal exposure monitoring PEM The approach will be to integrate KWJ ultralow power high performance printed amperometric gas sensor for key atmosp ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Validation of a Novel Treatment for Glioblastoma

    SBC: CURTANA PHARMACEUTICALS, INC.            Topic: NCI

    ? DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Utilization of cord blood-expanded stem cells for megakaryocyte and platelet production

    SBC: AllCells, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Platelet transfusions are the most effective treatments for patients with thrombocytopenia The growing demand for platelet transfusions is often limited by shortage in the platelets PTL supply due to dependency on volunteer donors short shelf life risk of infections and alloimmunization It is therefore critical to create an efficient donor independent ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. USE OF DNATrax TO MODEL THE TRANSPORT OF PARTICULATE MATTER IN URBAN ENVIRONMENTS

    SBC: DNATREK, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Science based strategies for quantifying and mitigating the impact of anthropogenic emissions on public health are essential for the sustainability of cities Similar strategies can also be used to develop and assess the effectiveness of a national defense system against terrorist attacks with airborne biological agents and protect against the spread of airborn ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain, safely and easily, sufficient cardiac transgene expression. Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery, approaches that are cumbersome to apply. Consequently, we have considered the u ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Transdermal Naltrexone for Opiate Addiction and Alcoholism

    SBC: ALLTRANZ, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic Antibodies for Biofilm Infections

    SBC: Trellis Bioscience, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Testing Smad7-based biologics for treating chronic wounds

    SBC: Taiga Biotechnologies, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Chronic skin wounds associated with various diseases (e.g., diabetes) and aberrant healing from acute wounding (e.g., hypertrophic scarring) is a major health care burden, which need scientific discovery-based therapeutic interventions. Our previous studies show that Smad7, a TGFb signaling antagonist, accelerates skin wound healing. We have developed a Smad7 f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting of Myc-Max dimerization for the treatment of cancer

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of hi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis

    SBC: XFIBRA, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government